Corcept has reached its take-profit ceiling at $83.09 with a negative risk/reward and 15% downside; two consecutive earnings misses have broken the prior beat streak, and a put/call ratio of 4.44 with 11% short interest signals heavy bearish market positioning — making the current setup unfavorable despite strong momentum readings.
Thesis pillars
- Price At Take Profit Negative Asymmetry↑Improving
- Two Consecutive Earnings Misses→Stable
- Elevated Put Call High Short Interest↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026· older than 90 days
Corcept Therapeutics Incorporat (CORT) Stock Analysis
Oversold Bounce setup
Healthcare · Biotechnology
Sell if holding. Momentum 4.5/10 is below the 5.0 floor at $79.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Counterparty: Curant; Concentration risk — Product: Products.
Corcept Therapeutics markets Korlym (mifepristone) and an authorized generic in the US for Cushing's syndrome (hypercortisolism) since 2012, with all revenue from these products collected by specialty pharmacy Curant Health. A relacorilant NDA for ovarian cancer has a PDUFA date... Read more
Sell if holding. Momentum 4.5/10 is below the 5.0 floor at $79.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Counterparty: Curant; Concentration risk — Product: Products. Chart setup: Oversold RSI 18, near Bollinger lower, volume surge. Score 6.2/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, news boost analyst 0.60, earnings proximity 111d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Corcept Therapeutics Incorporat
About Corcept Therapeutics Incorporat
Corcept Therapeutics has marketed Korlym (mifepristone) in the United States for hypercortisolism since 2012, adding an authorized generic in June 2024; all revenue flows from these two products for Cushing's syndrome. On December 30, 2025, the FDA issued a Complete Response Letter declining to approve relacorilant for hypercortisolism, while a second relacorilant NDA for ovarian cancer — accepted in September 2025 — carries a PDUFA date of July 11, 2026.
Korlym and its generic are distributed through Curant Health Georgia, LLC, which became the primary specialty pharmacy vendor in Q4 2025 following termination of the Optime Care relationship in October 2025; the Curant agreement runs to June 2028. Curant collects payments from insurers representing more than 99% of Corcept's revenue. The company's sales model targets physicians via sales representatives and medical science liaisons, with patient assistance programs funding co-pay support. Payer mix includes Medicare and Medicaid; the Inflation Reduction Act's Part D price negotiation program currently exempts orphan drugs indicated for only one rare disease — covering Korlym — and drugs with less than $200 million in annual Medicare expenditures. Generic competition from Teva entered in January 2024; the Federal Circuit affirmed no patent infringement on February 19, 2026, and litigation settlements with Sun Pharmaceutical and Hikma Pharmaceuticals allow those companies to enter commercially if Teva remains in the market.
Show full overview
The December 30, 2025 Complete Response Letter for the hypercortisolism NDA is the most immediate binary risk to Corcept's pipeline; the FDA required additional efficacy evidence despite the GRACE trial meeting its primary endpoint and the GRADIENT trial providing confirmatory data in patients with adrenal-etiology disease. The ovarian cancer indication carries a separate risk profile: the ROSELLA trial met dual primary endpoints for progression-free survival (hazard ratio 0.70, March 2025) and overall survival (hazard ratio 0.65, January 2026), supporting the July 11, 2026 PDUFA date, but any additional FDA request before that date could delay approval.
See also: Healthcare · Biotechnology
From Corcept Therapeutics Incorporat's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Oct 28, 2026Recent Developments — Corcept Therapeutics Incorporat
Latest news
- NEWS CORT Q3'26 Earnings: revenue estimate is 323.90M USD - TradingView — TradingView Oct 28, 2026 neutral
- NEWS Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Ya — Yahoo Finance Oct 27, 2026 neutral
- NEWS Can Corcept (NASDAQ:CORT) Advance Lifyorli After BELLA Trial Results? - Kalkine Media — Kalkine Media Oct 27, 2026 neutral
- NEWS Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail — The Globe and Mail Oct 27, 2026 positive
- NEWS Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Corcept Therapeutics (CORT) and Incyte (IN — The Globe and Mail Oct 27, 2026 neutral
Latest item Oct 28, 2026 · Generated 2026-11-05T11:34:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHcounterpartyCurant10-K Item 1A: 'Curant, dispenses our Products and performs related pharmacy and patient support services, including the collection of payments from insurers representing more than 99 percent of our revenue'
- HIGHProductProducts10-K Item 1A: 'Our ability to generate revenue and to fund our commercial operations and development programs is dependent on the sale of our Products to treat patients with hypercortisolism'
- HIGHpipelinerelacorilant10-K Item 1: 'On December 30, 2025, the FDA issued a Complete Response Letter ("CRL") declining to approve relacorilant'
Material Events(8-K, last 90d)
- 2026-05-28Item 5.02LOWOn May 21, 2026, shareholders approved an Amendment to the Corcept Therapeutics 2024 Incentive Award Plan, adding 8,000,000 shares to the plan. No officer departure or appointment disclosed under this item.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 4.5/10 is below the 5.0 floor at $79.22 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Counterparty: Curant; Concentration risk — Product: Products. Chart setup: Oversold RSI 18, near Bollinger lower, volume surge. Prior stop was $73.67. Score 6.2/10, moderate confidence.
Analyst target: $122.67 (+54.8% upside). Prior stop was $73.67. Stop-loss: $73.67.
Concentration risk — Counterparty: Curant; Concentration risk — Product: Products; Consecutive earnings misses (2).
Corcept Therapeutics Incorporat trades at a P/E of 59.6 (forward 18.8). TrendMatrix value score: 6.2/10. Verdict: Sell.
12 analysts rate CORT, with a consensus score of 3.9/5. 5 analysts publish price targets averaging $141.
What does Corcept Therapeutics Incorporat do?Corcept Therapeutics markets Korlym (mifepristone) and an authorized generic in the US for Cushing's syndrome...
Corcept Therapeutics markets Korlym (mifepristone) and an authorized generic in the US for Cushing's syndrome (hypercortisolism) since 2012, with all revenue from these products collected by specialty pharmacy Curant Health. A relacorilant NDA for ovarian cancer has a PDUFA date of July 11, 2026; a separate relacorilant NDA for hypercortisolism received a Complete Response Letter on December 30, 2025.